Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All saline studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSalineSaline (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Efficacy of BREATHOX® Device Inhalation on Acute Symptoms Associated with COVID-19 (BREATH Study): A Randomized Pilot Clinical Trial

Tanni et al., Journal of Clinical Medicine, doi:10.3390/jcm12186075
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 75% Improvement Relative Risk Recovery, fever -10% Recovery, cough 52% Recovery, sore throat 33% Recovery, dysgeusia 2% Recovery, anosmia -9% Saline  Tanni et al.  EARLY TREATMENT  RCT Is early treatment with saline beneficial for COVID-19? RCT 98 patients in Brazil Lower hospitalization with saline (not stat. sig., p=0.34) c19early.org Tanni et al., J. Clinical Medicine, Sep 2023 Favorssaline Favorscontrol 0 0.5 1 1.5 2+
RCT 98 outpatients in Brazil, showing faster recovery from cough with inhaled hypertonic saline. Authors note that the effect on coughing may hypothetically be related to a hyperosmotic response influencing the function of different membrane channels and preventing virus entry into the cells; and that the hypertonic solution may increase mucociliary clearance and reduce the destructive inflammatory process in the airways with a decrease in respiratory symptoms.
risk of hospitalization, 74.8% lower, RR 0.25, p = 0.34, treatment 0 of 65 (0.0%), control 1 of 33 (3.0%), NNT 33, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no recovery, 9.9% higher, HR 1.10, p = 0.70, treatment 65, control 33, inverted to make HR<1 favor treatment, fever.
risk of no recovery, 52.4% lower, HR 0.48, p = 0.009, treatment 65, control 33, inverted to make HR<1 favor treatment, cough.
risk of no recovery, 32.9% lower, HR 0.67, p = 0.11, treatment 65, control 33, inverted to make HR<1 favor treatment, sore throat.
risk of no recovery, 2.0% lower, HR 0.98, p = 0.94, treatment 65, control 33, inverted to make HR<1 favor treatment, dysgeusia.
risk of no recovery, 8.7% higher, HR 1.09, p = 0.74, treatment 65, control 33, inverted to make HR<1 favor treatment, anosmia.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tanni et al., 20 Sep 2023, Randomized Controlled Trial, Brazil, peer-reviewed, 20 authors. Contact: robsonapp@gmail.com (corresponding author), suzanapneumo@gmail.com, felipedamatto@hotmail.com, ctbredaneto@gmail.com, lrs.oliveira@unesp.br, luanapagan@alunos.fmb.unesp.br, marianagatto11@hotmail.com, leticiadv@gmail.com, lianascoelho@gmail.com, dianerezende@gmail.com, lh.machado@unesp.br, gustavo.mota@unesp.br, marina.monte@unesp.br, felipe.santaella@unesp.br, elisenf21@gmail.com, mcallegari10@gmail.com, marina.okoshi@unesp.br, fcwehrmeister@gmail.com, estefania.franco@unesp.br, ulw@rn.dk.
This PaperSalineAll
Efficacy of BREATHOX® Device Inhalation on Acute Symptoms Associated with COVID-19 (BREATH Study): A Randomized Pilot Clinical Trial
Suzana Tanni, Fernando Wehrmeister, Robson Prudente, Felipe Damatto, Carlos Breda Neto, Leiliane Oliveira, Luana Pagan, Mariana Gatto, Letícia Vieira, Liana Coelho, Diane Rezende, Luiz Machado, Gustavo Mota, Marina Gaiato, Felipe Santaella, Elisângela Campos, Estefânia Franco, Matheus Callegari, Marina Politi Okoshi, Ulla Weinreich
Journal of Clinical Medicine, doi:10.3390/jcm12186075
1) Background: A high concentration of sodium chloride on in vitro cell culture leads to reduced SARS-CoV-2 replication. Therefore, our aim was to evaluate the effects of inhaling hypertonic NaCl particles (BREATHOX ® ) on the duration of COVID-19-induced acute symptoms. (2) Methods: A prospective, open label, randomized, standard of care-controlled group (SOC) pilot trial compared inhaled oral and nasal administered BREATHOX ® (2.0 mg NaCl, particles size between 1-10 µm), with five or ten inhalations per day for ten days. The primary endpoint was the time to resolve COVID-19-related symptoms. Safety outcomes included adverse clinical and laboratory events. (3) Results: A total of 101 individuals were screened and 98 were randomly assigned to BREATHOX ® ten sessions per day (Group 1; 33 patients), BREATHOX ® five sessions per day (Group 2; 32 patients), or SOC (33 patients), and followed up for 28 days. There was an association with cough frequency after 10 days BREATHOX ® compared to SOC [Group 1: hazard ratio (HR) 2.01, 95% confidence interval (CI) 1.06-3.81; Group 2: HR 2.17, 95% CI 1.17-4.04]. No differences between the groups for the reported symptoms' resolution time were seen after 28 days. After combining both BREATHOX ® groups, the period to cough resolution 10 days after randomization was significantly lower than in SOC (HR 2.10,). An adverse event occurred in 30% of Group 1, 36% of Group 2, and 9% in SOC individuals. One patient from SOC had a serious adverse event. Nasal burning, sore or itchy nose, and dry mouth were considered related to BREATHOX ® use and resolved after stopping inhalations. (4) Conclusion: BREATHOX ® inhalation is safe and may be effective in reducing the duration of COVID-19-induced coughing.
Funding: This research was funded by LIITA Care. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee (Approval number 5.627.523). The study protocol was registered on the clinical trials registry (NCT05196581). All study activities, including project coordination, data management, and site monitoring were performed at the Botucatu Medical School, São Paulo State University, Brazil. The trial was overseen by a data-safety monitoring board of independent experts. Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
Brito, Braga, Cunha, Takenami, Mecanismos imunopatológicos envolvidos na infecção por SARS-CoV-2, J. Bras. Patol. Med. Lab
Chen, Geng, Xu, Chen, Gao et al., The features comparison between patients in the ICU and general wards and between patients with different outcomes: A 2020 COVID-19 study, Ann. Palliat. Med, doi:10.21037/apm-21-25
De Souza, Rivera, Almeida, Ge, De Souza et al., Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/Human Angiotensin-Converting Enzyme 2 Interaction, J. Phys. Chem. Lett, doi:10.1021/acs.jpclett.0c02602
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Jin, Cai, Cheng, Cheng, Deng et al., A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil. Med. Res, doi:10.1186/s40779-020-0233-6
Li, Geng, Peng, Meng, Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J. Pharm. Anal, doi:10.1016/j.jpha.2020.03.001
Machado, Glaser, Araujo, Petiz, Oliveira et al., Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells, ACS Pharmacol. Transl. Sci, doi:10.1021/acsptsci.1c00080
Rytilä, Lindqvist, Laitinen, Safety of sputum induction in chronic obstructive pulmonary disease, Eur. Respir. J, doi:10.1034/j.1399-3003.2000.01522.x
Schoeffei, Anderson, Altounyan, Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline, Br. Med. J, doi:10.1136/bmj.283.6302.1285
Taube, Holz, Mücke, Jorres, Magnussen, Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med, doi:10.1164/ajrccm.164.10.2104024
Tay, Poh, Rénia, Macary, Ng, The trinity of COVID-19: Immunity, inflammation and intervention, Nat. Rev. Immunol, doi:10.1038/s41577-020-0311-8
Wang, Ding, From SARS to COVID-19: Pathogens, receptor, pathogenesis and principles of the treatment, Zhonghua Bing Li Xue Za Zhi
Wark, Mcdonald, Nebulised hypertonic saline for cystic fibrosis, Cochrane Database Syst. Rev, doi:10.1002/14651858.CD001506.pub4
Who, WHO COVID-19 Dashboard
{ 'indexed': {'date-parts': [[2023, 9, 22]], 'date-time': '2023-09-22T05:09:40Z', 'timestamp': 1695359380985}, 'reference-count': 18, 'publisher': 'MDPI AG', 'issue': '18', 'license': [ { 'start': { 'date-parts': [[2023, 9, 20]], 'date-time': '2023-09-20T00:00:00Z', 'timestamp': 1695168000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'funder': [{'name': 'Liita Care'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>(1) Background: A high concentration of sodium chloride on in vitro cell culture ' 'leads to reduced SARS-CoV-2 replication. Therefore, our aim was to evaluate the effects of ' 'inhaling hypertonic NaCl particles (BREATHOX®) on the duration of COVID-19-induced acute ' 'symptoms. (2) Methods: A prospective, open label, randomized, standard of care-controlled ' 'group (SOC) pilot trial compared inhaled oral and nasal administered BREATHOX® (2.0 mg NaCl, ' 'particles size between 1–10 μm), with five or ten inhalations per day for ten days. The ' 'primary endpoint was the time to resolve COVID-19-related symptoms. Safety outcomes included ' 'adverse clinical and laboratory events. (3) Results: A total of 101 individuals were screened ' 'and 98 were randomly assigned to BREATHOX® ten sessions per day (Group 1; 33 patients), ' 'BREATHOX® five sessions per day (Group 2; 32 patients), or SOC (33 patients), and followed up ' 'for 28 days. There was an association with cough frequency after 10 days BREATHOX® compared ' 'to SOC [Group 1: hazard ratio (HR) 2.01, 95% confidence interval (CI) 1.06–3.81; Group 2: HR ' '2.17, 95% CI 1.17–4.04]. No differences between the groups for the reported symptoms’ ' 'resolution time were seen after 28 days. After combining both BREATHOX® groups, the period to ' 'cough resolution 10 days after randomization was significantly lower than in SOC (HR 2.10, ' '95% CI 1.20–3.67). An adverse event occurred in 30% of Group 1, 36% of Group 2, and 9% in SOC ' 'individuals. One patient from SOC had a serious adverse event. Nasal burning, sore or itchy ' 'nose, and dry mouth were considered related to BREATHOX® use and resolved after stopping ' 'inhalations. (4) Conclusion: BREATHOX® inhalation is safe and may be effective in reducing ' 'the duration of COVID-19-induced coughing.</jats:p>', 'DOI': '10.3390/jcm12186075', 'type': 'journal-article', 'created': {'date-parts': [[2023, 9, 21]], 'date-time': '2023-09-21T02:38:45Z', 'timestamp': 1695263925000}, 'page': '6075', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy of BREATHOX® Device Inhalation on Acute Symptoms Associated with COVID-19 (BREATH ' 'Study): A Randomized Pilot Clinical Trial', 'prefix': '10.3390', 'volume': '12', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2587-2759', 'authenticated-orcid': False, 'given': 'Suzana', 'family': 'Tanni', 'sequence': 'first', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Fernando', 'family': 'Wehrmeister', 'sequence': 'additional', 'affiliation': [ { 'name': 'Departament of Social Medicine, The Faculty of Medicine, Federal ' 'University of Pelotas, Avenida Duque de Caxias 250, Pelotas ' '96030-002, Rio Grande do Sul, Brazil'}]}, { 'given': 'Robson', 'family': 'Prudente', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Hospital of Botucatu Medical School, São Paulo State ' 'University (Unesp), Distrito de Rubião Junior s/n, Botucatu ' '18618-970, São Paulo, Brazil'}]}, { 'given': 'Felipe', 'family': 'Damatto', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Carlos', 'family': 'Breda Neto', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Leiliane', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Luana', 'family': 'Pagan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Mariana', 'family': 'Gatto', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Letícia', 'family': 'Vieira', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Liana', 'family': 'Coelho', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Diane', 'family': 'Rezende', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Luiz', 'family': 'Machado', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8103-3338', 'authenticated-orcid': False, 'given': 'Gustavo', 'family': 'Mota', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4060-870X', 'authenticated-orcid': False, 'given': 'Marina', 'family': 'Gaiato', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Felipe', 'family': 'Santaella', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0002-8529-7637', 'authenticated-orcid': False, 'given': 'Elisângela', 'family': 'Campos', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'given': 'Estefânia', 'family': 'Franco', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Hospital of Botucatu Medical School, São Paulo State ' 'University (Unesp), Distrito de Rubião Junior s/n, Botucatu ' '18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9557-3968', 'authenticated-orcid': False, 'given': 'Matheus', 'family': 'Callegari', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0001-7728-4505', 'authenticated-orcid': False, 'given': 'Marina Politi', 'family': 'Okoshi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical School, São Paulo State University (Unesp), Distrito de ' 'Rubião Junior s/n, Botucatu 18618-970, São Paulo, Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1975-3654', 'authenticated-orcid': False, 'given': 'Ulla', 'family': 'Weinreich', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Medicine, The Faculty of Medicine, ' 'Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, ' 'Denmark'}]}], 'member': '1968', 'published-online': {'date-parts': [[2023, 9, 20]]}, 'reference': [ { 'key': 'ref_1', 'unstructured': 'WHO (2020). WHO COVID-19 Dashboard, World Health Organization. Available ' 'online: https://covid19.who.int/.'}, { 'key': 'ref_2', 'doi-asserted-by': 'crossref', 'first-page': '363', 'DOI': '10.1038/s41577-020-0311-8', 'article-title': 'The trinity of COVID-19: Immunity, inflammation and intervention', 'volume': '20', 'author': 'Tay', 'year': '2020', 'journal-title': 'Nat. Rev. Immunol.'}, { 'key': 'ref_3', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical Characteristics of Coronavirus Disease 2019 in China', 'volume': '382', 'author': 'Guan', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref_4', 'doi-asserted-by': 'crossref', 'first-page': '672', 'DOI': '10.21037/apm-21-25', 'article-title': 'The features comparison between patients in the ICU and general wards ' 'and between patients with different outcomes: A 2020 COVID-19 study', 'volume': '10', 'author': 'Chen', 'year': '2021', 'journal-title': 'Ann. Palliat. Med.'}, { 'key': 'ref_5', 'doi-asserted-by': 'crossref', 'first-page': 'P497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'ref_6', 'unstructured': 'COVID-19 Treatment Guidelines Panel (2023, April 22). Coronavirus ' 'Disease 2019 (COVID-19) Treatment Guidelines, Available online: ' 'https://www.covid19treatmentguidelines.nih.gov/.'}, { 'key': 'ref_7', 'first-page': 'e3352020', 'article-title': 'Mecanismos imunopatológicos envolvidos na infecção por SARS-CoV-2', 'volume': '56', 'author': 'Brito', 'year': '2020', 'journal-title': 'J. Bras. Patol. Med. Lab.'}, { 'key': 'ref_8', 'first-page': '4', 'article-title': 'A rapid advice guideline for the diagnosis and treatment of 2019 novel ' 'coronavirus (2019-nCoV) infected pneumonia (standard version)', 'volume': '7', 'author': 'Jin', 'year': '2020', 'journal-title': 'Mil. Med. Res.'}, { 'key': 'ref_9', 'doi-asserted-by': 'crossref', 'first-page': '102', 'DOI': '10.1016/j.jpha.2020.03.001', 'article-title': 'Molecular immune pathogenesis and diagnosis of COVID-19', 'volume': '10', 'author': 'Li', 'year': '2020', 'journal-title': 'J. Pharm. Anal.'}, { 'key': 'ref_10', 'first-page': '647', 'article-title': 'From SARS to COVID-19: Pathogens, receptor, pathogenesis and principles ' 'of the treatment', 'volume': '49', 'author': 'Wang', 'year': '2020', 'journal-title': 'Zhonghua Bing Li Xue Za Zhi'}, { 'key': 'ref_11', 'doi-asserted-by': 'crossref', 'first-page': '1514', 'DOI': '10.1021/acsptsci.1c00080', 'article-title': 'Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 ' 'Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial ' 'Cells', 'volume': '4', 'author': 'Machado', 'year': '2021', 'journal-title': 'ACS Pharmacol. Transl. Sci.'}, { 'key': 'ref_12', 'doi-asserted-by': 'crossref', 'first-page': '10446', 'DOI': '10.1021/acs.jpclett.0c02602', 'article-title': 'Molecular Dynamics Reveals Complex Compensatory Effects of Ionic ' 'Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 ' 'Spike/Human Angiotensin-Converting Enzyme 2 Interaction', 'volume': '11', 'author': 'Rivera', 'year': '2020', 'journal-title': 'J. Phys. Chem. Lett.'}, { 'key': 'ref_13', 'unstructured': 'World Health Organization (2020). WHO R&D Blueprint Novel Coronavirus ' 'COVID-19 Therapeutic Trial Synopsis, World Health Organization.'}, { 'key': 'ref_14', 'doi-asserted-by': 'crossref', 'first-page': '1285', 'DOI': '10.1136/bmj.283.6302.1285', 'article-title': 'Bronchial hyperreactivity in response to inhalation of ultrasonically ' 'nebulised solutions of distilled water and saline', 'volume': '283', 'author': 'Schoeffei', 'year': '1981', 'journal-title': 'Br. Med. J.'}, { 'key': 'ref_15', 'first-page': 'CD001506', 'article-title': 'Nebulised hypertonic saline for cystic fibrosis', 'volume': '2018', 'author': 'Wark', 'year': '2018', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': 'ref_16', 'doi-asserted-by': 'crossref', 'first-page': '1810', 'DOI': '10.1164/ajrccm.164.10.2104024', 'article-title': 'Airway response to inhaled hypertonic saline in patients with moderate ' 'to severe chronic obstructive pulmonary disease', 'volume': '164', 'author': 'Taube', 'year': '2001', 'journal-title': 'Am. J. Respir. Crit. Care Med.'}, { 'key': 'ref_17', 'doi-asserted-by': 'crossref', 'first-page': '1116', 'DOI': '10.1034/j.1399-3003.2000.01522.x', 'article-title': 'Safety of sputum induction in chronic obstructive pulmonary disease', 'volume': '15', 'author': 'Lindqvist', 'year': '2000', 'journal-title': 'Eur. Respir. J.'}, { 'key': 'ref_18', 'unstructured': '(2023, April 22). COVID-19 Rapid Guideline: Managing COVID-19—The ' 'National Institute for Health and Care Excellence (NICE). 28.0 published ' 'on 29.03.2023. Available online: ' 'https://www.nice.org.uk/guidance/ng191.'}], 'container-title': 'Journal of Clinical Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/2077-0383/12/18/6075/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 21]], 'date-time': '2023-09-21T03:27:40Z', 'timestamp': 1695266860000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/2077-0383/12/18/6075'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 9, 20]]}, 'references-count': 18, 'journal-issue': {'issue': '18', 'published-online': {'date-parts': [[2023, 9]]}}, 'alternative-id': ['jcm12186075'], 'URL': 'http://dx.doi.org/10.3390/jcm12186075', 'relation': {}, 'ISSN': ['2077-0383'], 'subject': ['General Medicine'], 'container-title-short': 'JCM', 'published': {'date-parts': [[2023, 9, 20]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit